DK3766884T3 - Krystalform og salttype af triazolopyrimidinforbindelse og fremstillingsfremgangsmåde dertil - Google Patents

Krystalform og salttype af triazolopyrimidinforbindelse og fremstillingsfremgangsmåde dertil Download PDF

Info

Publication number
DK3766884T3
DK3766884T3 DK19793622.2T DK19793622T DK3766884T3 DK 3766884 T3 DK3766884 T3 DK 3766884T3 DK 19793622 T DK19793622 T DK 19793622T DK 3766884 T3 DK3766884 T3 DK 3766884T3
Authority
DK
Denmark
Prior art keywords
crystal form
manufacturing procedure
salt type
triazolopyrimidine compound
triazolopyrimidine
Prior art date
Application number
DK19793622.2T
Other languages
Danish (da)
English (en)
Inventor
Kevin X Chen
Yanxin Yu
Xinde Chen
Li Zhang
Zhaoguo Chen
Cheng Xie
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Application granted granted Critical
Publication of DK3766884T3 publication Critical patent/DK3766884T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK19793622.2T 2018-04-28 2019-04-28 Krystalform og salttype af triazolopyrimidinforbindelse og fremstillingsfremgangsmåde dertil DK3766884T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810399876 2018-04-28
PCT/CN2019/084822 WO2019206336A1 (zh) 2018-04-28 2019-04-28 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法

Publications (1)

Publication Number Publication Date
DK3766884T3 true DK3766884T3 (da) 2022-03-28

Family

ID=68294924

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19793622.2T DK3766884T3 (da) 2018-04-28 2019-04-28 Krystalform og salttype af triazolopyrimidinforbindelse og fremstillingsfremgangsmåde dertil

Country Status (9)

Country Link
US (1) US11649239B2 (enExample)
EP (1) EP3766884B1 (enExample)
JP (1) JP7406691B2 (enExample)
CN (1) CN112105617B (enExample)
DK (1) DK3766884T3 (enExample)
ES (1) ES2908424T3 (enExample)
PL (1) PL3766884T3 (enExample)
PT (1) PT3766884T (enExample)
WO (1) WO2019206336A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649239B2 (en) * 2018-04-28 2023-05-16 Medshine Discovery Inc. Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)
TWI820209B (zh) * 2018-09-12 2023-11-01 大陸商迪哲(江蘇)醫藥股份有限公司 三唑并-嘧啶化合物及其用途
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
MX2022002219A (es) * 2019-08-26 2022-06-14 Incyte Corp Triazolopirimidinas como inhibidores de a2a/a2b.
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284737C (en) 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
AU2003272886A1 (en) 2002-09-24 2004-04-19 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE
JP7065113B2 (ja) 2017-04-07 2022-05-11 南京明徳新薬研発有限公司 A2A受容体阻害剤としての[1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体
US11649239B2 (en) * 2018-04-28 2023-05-16 Medshine Discovery Inc. Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)

Also Published As

Publication number Publication date
EP3766884A1 (en) 2021-01-20
PL3766884T3 (pl) 2022-07-18
CN112105617A (zh) 2020-12-18
US20210094957A1 (en) 2021-04-01
WO2019206336A1 (zh) 2019-10-31
PT3766884T (pt) 2022-03-31
JP2021522335A (ja) 2021-08-30
EP3766884A4 (en) 2021-03-31
EP3766884B1 (en) 2022-02-09
ES2908424T3 (es) 2022-04-29
JP7406691B2 (ja) 2023-12-28
CN112105617B (zh) 2022-04-05
US11649239B2 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
DK3810581T3 (da) Krystalmodifikationer af odevixibat
IL288997A (en) Salt forms of bempedoic acid and methods for using the same
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
CA200056S (fr) Bracelet
DK3964510T3 (da) Krystalform af wee1-hæmmerforbindelse og anvendelse deraf
ZA202007037B (en) Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
DK3740326T3 (da) Fremgangsmåder til fremstilling af optiske effektlag
DK3596042T3 (da) Krystalformer af aminolipider
IL283526A (en) D-psicose crystal and preparation method therefor
IL286218A (en) Solid state forms of ripretinib
DK3470400T3 (da) Krystallinske former af ozanimod og ozanimodhydrochlorid samtfremgangsmåder til fremstilling deraf
DK3894012T3 (da) Krystallinske former og saltformer af en kinasehæmmer
EP3729174C0 (en) Triple mosaic lenses providing a wide field of vision
DK3412674T3 (da) Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser
FIC20260011I1 (fi) nirogasestaatin dihydrobromidisuolan kiteinen muoto
PL4046129T3 (pl) Sposób wytwarzania
EP3767363C0 (en) WIDE FIELD OF VIEW OBJECTIVE LENS
EP4329759A4 (en) CRYSTALLINE FORMS OF LSD SALTS
PL3942107T3 (pl) Sposób wytwarzania
DK3636640T3 (da) Krystal af heterocyclidenacetamidderivat
DK3529236T3 (da) Krystalformer af eravacyclin
PT3766884T (pt) Forma cristalina e tipo de sal de composto de triazolopirimidina e método de preparação associado
DK3743064T3 (da) Behandling af proteinuri
DK3749673T3 (da) Krystallinsk form af bictegravir-natrium
DK3511333T3 (da) Krystalform og saltform af 7h-pyrrolo[2,3-d]pyrimidinforbindelse og fremgangsmåde til fremstilling deraf